Advanced search
Publication Cover
Expert Review of Obstetrics & Gynecology Volume 8, 2013 - Issue 5
Journal homepage
24
Views
1
CrossRef citations to date
0
Altmetric
Reviews

Advances in the treatment of vulvovaginal atrophy

Jill M KrapfThe George Washington University Medical Faculty Associates, 2300 M Street NW, Washington DC 200037, USACorrespondence[email protected]
,
Zoe R BelkinThe Centers for Vulvovaginal Disorders, 3 Washington Circle NW, Washington DC 20037, USA
&
Andrew T GoldsteinThe Centers for Vulvovaginal Disorders, 3 Washington Circle NW, Washington DC 20037, USA
Pages 457-465 | Published online: 10 Jan 2014

References

  • North American Menopause Society. The role of local vaginal estrogen for the treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 14, 355–369 (2007).
  • Calleja-Agius J, Brincat MP. Urogenital atrophy. Climacteric 12(4), 279–285 (2009).
  • North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 17(2), 242–255 (2010).
  • North American Menopause Society. The 2012 hormone therapy position statement: of: The North American Menopause Society. Menopause 19(3), 257–271 (2012).
  • Pandit L, Ouslander J. Postmenopausal vaginal atrophy and atrophic vaginitis. Am. J. Med. Sci. 314(4), 228–231 (1997).
  • Nachtigall L, Nachigall M, Goren J, Loweenstein J. Update on vaginal atrophy. Menopause Manag. 17–19 (2005).
  • Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Julia MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52, S46–52 (2005).
  • Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J. Sex Med. 2(Suppl. 3), 154–165 (2005).
  • Iosif CS, Batra S, Ek A, Astedt B. Estrogen receptors in the human female lower urinary tract. Am. J. Obstet. Gynecol. 141(7), 817–820 (1981).
  • Bergmen A, Karram MM, Bhatia NN. Changes in urethral cytology following estrogen administration. Gynecol. Obstet. Invest. 29(3), 211–213 (1990).
  • Robinson D, Cardozo L. The roles of estrogens in female lower urinary tract dysfunction. Urology 62, 45–51 (2003).
  • Bachmann G, Nevadunsky N. Diagnosis and treatment of atrophic vaginitis. Am. Fam. Physician 61, 3090–3096 (2000).
  • Ibe C, Simon JA. Vulvovaginal atrophy: Current and future therapies. J. Sex Med. 7, 1042–1050 (2010).
  • Labrie F, Archer A, Bouchard C et al. Effect of intravaginaldehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women. Menopause 16(5), 923–931, 2009.
  • Berger L, El-Alfy M, Martel C, Labrie F. Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina. J. Steroid Biochem. Mol. Biol. 96(2), 201–215, 2005.
  • Suckling J, Lethaby A Kennedy R. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. 4. CD001500 (2006).
  • Johnston SL, Farrell SA, Bouchard C et al. The detection and management of vaginal atrophy. J. Obstet. Gynaecol. Can. 26, 503–515 (2004).
  • Long CY, Liu CM, Hsu SC et al. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 13, 727–743 (2006).
  • Simon J, Nachtigall L, Gut R et al. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet. Gynecol. 112, 1053–1060 (2009).
  • Al-Baghdadi O, Ewies AA. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview. Climacteric 12, 91–105 (2009).
  • Irwin Goldstein. Hormonal Factors in Women’s Sexual Pain Disorders. P180–195 In: Female Sexual Pain Disorders: Evaluation and Management. Goldstein A, Pukall C, Goldstein I ( Eds). Blackwell Publishing Ltd, Blackwell-Wiley, UK (2009).
  • Mattisson LA, Ericsson A, Bogelund M, Maamari R. Women’s preference toward attributes of local estrogen therapy for treatment of vaginal atrophy. Maturitas 74(3), 259–263 (2013).
  • Cano A, Estevez J, Usandizaga R et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause 19(10), 1130–1139 (2012).
  • Shelly W, Draper MW, Krishnan V, Wong M, Jaffe RB. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet. Gynecol. Surv. 63, 163–181 (2008).
  • Wurz GT, Soe LH, DeGregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas 74, 220–225 (2013).
  • Pickar JH. Emerging therapies for postmenopausal vaginal atrophy. Maturitas 75, 3–6 (2013).
  • Bachmann GA, Komi JO. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause 17, 480–486 (2010).
  • Goldstein SR, Cummings SR, Eastell R, Ensrud K et al. Vaginal effects of lasofoxifene: 3-year results from the PEARL Trial. Menopause 15, 1228 (2008).
  • Goldstein SR, Neven P, Cummings S et al. Postmenopausal evaluation and risk reduction with Lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause 18(1), 17–22 (2011).
  • Tan O, Bradshaw K, Carr BR. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review. Menopause 19(1), 109–117 (2012).
  • Schmidt, C. Third-generation SERMS may face uphill battle. J. Natl Cancer Inst. 102(22), 1690–1692 (2010).
  • Archer DR. Tissue-selective estrogen complexes: a promising option for the comprehensive management of postmenopausal symptoms. Drugs Aging 27, 533–544 (2010).
  • Lobo RA, Pinkerton JV, Gass ML et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil. Steril. 92, 1025–1038 (2009).
  • Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil. Steril. 92, 1018–1024 (2009).
  • Kagan R, Williams RS, Pan K, Mirkin S, Pickar JH. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. Menopause 17(2), 281–289 (2010).
  • Pessina MA, Hoyt RF, Goldstein I, Traish AM. Differential regulation of the expression of estrogen, progesterone, and androgen receptor by sex steroid hormones in the vagina: Immunohistochemical studies. J. Sex Med. 3, 804–814 (2006).
  • Baldassarre M, Perrone AM, Giannone FA et al. Androgen receptor expression in the human vagina under different physiological and treatment conditions. Int. J. Impot. Res. 25, 7–11 (2013).
  • Krapf JM, Simon JA. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas 63(3), 213–219 (2009).
  • Berman JR, Almeida FG, Jolin J, Raz S, Chaudhuri G, Gonzalez-Cadavid NF. Correlation of androgen receptors, aromatase and 5-alpha reductase in the human vagina with menopausal status. Fertil. Steril. 79, 925–931 (2003).
  • Traish AM, Kim N, Min K, Muarriz R, Goldstein I. Role of androgens in female genital sexual arousal: receptor expression, structure and function. Fertil. Steril. 77(4), S11–18 (2002).
  • Witherby S, Johnson J, Demers L et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 16, 424–431 (2011).
  • Panjani M, Bell RJ, Jane F et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J. Sex Med. 6(9), 2579–2590 (2009).
  • Labrie F, Cusan L, Gomez JL et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J. Steroid. Biochem. Mol. Biol. 111, 178–194 (2008).
  • Labrie F, Archer D, Bouchard C et al. Effect of intravaginaldehydroepiandrosterone (Prasterone) on libido and sexual function in postmenopausal women. Menopause 16(5), 923–931 (2009).
  • Labrie F, Archer D, Bouchard C et al. Intravaginaldehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia. Climacteric 14, 282–288 (2011).
  • Jonasson AF, Edwall L, Uvnas-Moberg K. Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study. Menopause Int. 17, 120–125 (2011).
  • Bedell S, Nachtigall M, Naftolin F. The pros and cons of plant estrogens for menopause. J. Steroid Biochem. Mol. Biol. (2013) ( In press). http://www.sciencedirect.com/science/journal/aip/09600760. Accessed April 18, 2013.
  • Le Donne M, Caruso C, Manscuso A et al. The effect of vaginally administered genistein in comparison with hyaluronic acid on atrophic epithelium in postmenopause. Archiv. Gynecol. Obstet. 283, 1319–1323 (2011).
  • Lima SM, Yamada SS, Reis BF, Sostenes P et al. Effective treatment of vaginal atrophy with isoflavone vaginal gel. Maturitas 74(3), 252–258 (2013).
  • Stika CS. Atrophic vaginitis. Dermatol. Ther. 23, 514–522 (2010).
  • Sinha A, Ewies AA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric (2013) (In print). http://informahealthcare.com/doi/abs/10.3109/13697137.2012.756466?journalCode=cmt. ( Accessed April 18, 2013).
  • Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil. Steril. 61, 178–180 (1994).
  • Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas 23(3), 259–263 (1996).
  • Van der Laak, JA, de Bie LM, de Leeuw H et al. The effects of Replens on vaginal cytology in the treatment of postmenopausal atrophy: Cytomorphology versus computerized cytometry. J. Clin. Pathol. 55(6), 446–451 (2002).
  • Loprinzi CL, Abu-Ghazaleh S, Sloan JA et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J. Clin. Oncol. 15(3), 969–973 (1997).
  • Ekin M, Yasar L, Kadir S, Muzaffer T, Mehmet U, Gencer I, Kivanc E. The comparison of hyaluronic acid vaginal tablets with estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized control trial. Archiv. Gynecol. Obstet. 283(3), 539–543 (2011).
  • Chen J, Geng L, Song X, Li H, Giordan N, Liao Q. Evaluation of the efficacy and safety of hyaluronic acid vaginal gel to ease vaginal dryness: A multicenter, randomized, controlled, open-label, parallel-group, clinical trial. JSM (2013); Epub ahead of print. http://onlinelibrary.wiley.com/doi/10.1111/jsm.12125/abstract. ( Accessed April 18, 2013).
  • Lee YK, Chung HH, Kim JW et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors. Obstet. Gynecol. 117(4), 922–927 (2011).

Patent

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.